Prognostic value of serum albumin-creatinine ratio as a biomarker in patients treated with immune checkpoint inhibitors.

IF 2.7 4区医学 Q3 IMMUNOLOGY

Immunotherapy Pub Date : 2025-06-05 DOI:10.1080/1750743X.2025.2513850

Onur Bas, Mert Tokatlı, Naciye Guduk, Dilara Erdoğan, Nur Evşan Boyraz, Gözde Kavgaci, Taha Koray Sahin, Deniz Can Guven, Neyran Kertmen, Sercan Aksoy, Mustafa Erman, Şuayib Yalcin, Ömer Dizdar

{"title":"Prognostic value of serum albumin-creatinine ratio as a biomarker in patients treated with immune checkpoint inhibitors.","authors":"Onur Bas, Mert Tokatlı, Naciye Guduk, Dilara Erdoğan, Nur Evşan Boyraz, Gözde Kavgaci, Taha Koray Sahin, Deniz Can Guven, Neyran Kertmen, Sercan Aksoy, Mustafa Erman, Şuayib Yalcin, Ömer Dizdar","doi":"10.1080/1750743X.2025.2513850","DOIUrl":null,"url":null,"abstract":"Background: Albumin and creatinine are considered important for understanding patient response to immune checkpoint inhibitors (ICIs). However, numerous confounding factors complicate the interpretation of albumin and creatinine alone in clinical practice. This study aims to assess the correlation between survival outcomes and serum-albumin creatinine ratio (sACR) in patients treated with ICIs.Methods: This study was conducted on individuals who received at least three doses of ICI between 2018 and 2023. Patients were divided into two groups, sACR-High and sACR-Low, based on the median level. The relationship between sACR and survival outcomes was analyzed using a cox regression model. The relationship between sACR and early progression, late progression, and long-term benefit was analyzed using a logistic regression model.Results: Patients with lower sACR had decreased overall survival (OS) (HR: 1.42, 95% CI 1.07-1.89, p = 0.014) and progression-free survival (PFS) (HR: 1.34, 95% CI 1.08-1.66, p = 0.009). sACR was associated with early progression (HR: 1.86, 95% CI, 1.14-3.01, p = 0.012), late progression (HR: 2.06, 95 % CI 1.0-4.24, p = 0.050), and long-term benefit of ICIs (HR: 1.72, 95% CI 1.002-2.93, p = 0.049).Conclusions: Our study demonstrated that sACR could serve as an independent predictor of OS, PFS, early progression, late progression, and long-term benefit in patients treated with ICIs.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1-9"},"PeriodicalIF":2.7000,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1750743X.2025.2513850","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Albumin and creatinine are considered important for understanding patient response to immune checkpoint inhibitors (ICIs). However, numerous confounding factors complicate the interpretation of albumin and creatinine alone in clinical practice. This study aims to assess the correlation between survival outcomes and serum-albumin creatinine ratio (sACR) in patients treated with ICIs.

Methods: This study was conducted on individuals who received at least three doses of ICI between 2018 and 2023. Patients were divided into two groups, sACR-High and sACR-Low, based on the median level. The relationship between sACR and survival outcomes was analyzed using a cox regression model. The relationship between sACR and early progression, late progression, and long-term benefit was analyzed using a logistic regression model.

Results: Patients with lower sACR had decreased overall survival (OS) (HR: 1.42, 95% CI 1.07-1.89, p = 0.014) and progression-free survival (PFS) (HR: 1.34, 95% CI 1.08-1.66, p = 0.009). sACR was associated with early progression (HR: 1.86, 95% CI, 1.14-3.01, p = 0.012), late progression (HR: 2.06, 95 % CI 1.0-4.24, p = 0.050), and long-term benefit of ICIs (HR: 1.72, 95% CI 1.002-2.93, p = 0.049).

Conclusions: Our study demonstrated that sACR could serve as an independent predictor of OS, PFS, early progression, late progression, and long-term benefit in patients treated with ICIs.

查看原文本刊更多论文

血清白蛋白-肌酐比值作为免疫检查点抑制剂治疗患者的生物标志物的预后价值

背景：白蛋白和肌酐被认为是了解患者对免疫检查点抑制剂（ICIs）反应的重要指标。然而，在临床实践中，许多混杂因素使白蛋白和肌酐单独的解释复杂化。本研究旨在评估ICIs患者的生存结果与血清白蛋白肌酐比值（sACR）之间的相关性。方法：本研究对2018年至2023年期间接受至少三剂ICI的个体进行了研究。根据中位水平将患者分为sacr -高和sacr -低两组。采用cox回归模型分析sACR与生存结局的关系。采用logistic回归模型分析sACR与早期进展、晚期进展和长期获益的关系。结果：sACR较低的患者总生存期（OS）（HR: 1.42, 95% CI 1.07-1.89, p = 0.014）和无进展生存期（PFS）（HR: 1.34, 95% CI 1.08-1.66, p = 0.009）降低。sACR与早期进展（HR: 1.86, 95% CI: 1.14-3.01, p = 0.012）、晚期进展（HR: 2.06, 95% CI 1.0-4.24, p = 0.050）和ICIs的长期获益（HR: 1.72, 95% CI: 1.002-2.93, p = 0.049）相关。结论：我们的研究表明，sACR可以作为独立的预测因素，预测接受ICIs治疗的患者的OS、PFS、早期进展、晚期进展和长期获益。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Immunotherapy 医学-免疫学

CiteScore

5.00

自引率

3.60%

发文量

113

审稿时长

6-12 weeks

期刊介绍： Many aspects of the immune system and mechanisms of immunomodulatory therapies remain to be elucidated in order to exploit fully the emerging opportunities. Those involved in the research and clinical applications of immunotherapy are challenged by the huge and intricate volumes of knowledge arising from this fast-evolving field. The journal Immunotherapy offers the scientific community an interdisciplinary forum, providing them with information on the most recent advances of various aspects of immunotherapies, in a concise format to aid navigation of this complex field. Immunotherapy delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this vitally important area of research. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.